ArticleProceedings of the National Academy of Sciences of the United States of America1998
Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 537 citations in OpenAlex.
- Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing.Blood · 2026Article
- G protein-coupled receptor-mediated platelet thrombus formation.Current opinion in hematology · 2026Review
- Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Platelets cause microvascular occlusion and delayed neurological deficits after subarachnoid hemorrhage in mice.Experimental & molecular medicine · 2026Article
- Chrysotoxine Attenuates Key Atherogenic Processes via Antioxidant, Anti-Inflammatory, and COX-Dependent Antiplatelet Mechanisms.Biomolecules · 2026Article
- Transmembrane Transport of cAMP and AMP Using a Two Component Small Molecule Transport System.Angewandte Chemie (International ed. in English) · 2026Article
- Antiplatelet Therapy.Handbook of experimental pharmacology · 2026Review
- Purinergic P2YPurinergic signalling · 2025Article
- Design and Pharmacological Characterization of a Novel Antithrombotic P2YInternational journal of molecular sciences · 2025Article
- Purinergic signaling in the battlefield of viral infections.Purinergic signalling · 2025Review
- Article
- Identifiability of enzyme kinetic parameters in substrate competition: a case study of CD39/NTPDase1.Purinergic signalling · 2024Article
- Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes.International journal of molecular sciences · 2024Review
- Exploring bias in platelet P2YBritish journal of pharmacology · 2024Review
- Blood oxygen regulation via P2Y12R expressed in the carotid body.Respiratory research · 2024Article
- Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics.Current pharmaceutical design · 2024Review
- Role of Prednisolone in Platelet Activation by Inhibiting TxAAnimals : an open access journal from MDPI · 2023Article
- Antiplatelet Effect of Daphnetin Is Regulated by cPLAInternational journal of molecular sciences · 2023Article
- Platelet P2YBMC biology · 2023Article
- Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease.BMC cardiovascular disorders · 2022Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ADP is an important platelet agonist causing shape change and aggregation required for physiological hemostasis. We recently demonstrated the existence of two distinct G protein-coupled ADP receptors on platelets, one coupled to phospholipase C, P2Y1, and the other to inhibition of adenylyl cyclase, P2TAC. In this study, using specific antagonists for these two receptors, we demonstrated that concomitant intracellular signaling from both the P2TAC and P2Y1 receptors is essential for ADP-induced platelet aggregation. Inhibition of signaling through either receptor, by specific antagonists, is sufficient to block ADP-induced platelet aggregation. Furthermore, signaling through the P2TAC receptor could be replaced by activation of alpha2A-adrenergic receptors. On the other hand, activation of serotonin receptors supplements signaling through the P2Y1 receptor. Moreover, this mechanism of ADP-induced platelet aggregation could be mimicked by coactivation of two non-ADP receptors coupled to Gi and Gq, neither of which can cause platelet aggregation by itself. We propose that platelet aggregation results from concomitant signaling from both the Gi and Gq, a mechanism by which G protein-coupled receptors elicit a physiological response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.